Cargando…
The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis
The main manifestation of systemic sclerosis (SSc) is the overproduction of extracellular matrix, predominantly type I collagen. This study was undertaken to evaluate the effects of noncytotoxic doses of the topoisomerase I inhibitor camptothecin (CPT) on collagen production in the activated dermal...
Autores principales: | Czuwara-Ladykowska, Joanna, Makiela, Barbara, Smith, Edwin A, Trojanowska, Maria, Rudnicka, Lidia |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64844/ https://www.ncbi.nlm.nih.gov/pubmed/11549373 |
Ejemplares similares
-
New Topoisomerase I mutations are associated with resistance to camptothecin
por: Gongora, Céline, et al.
Publicado: (2011) -
Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis
por: Stochmal, Anna, et al.
Publicado: (2019) -
Characterization of DNA Topoisomerase-1 in Spodoptera exigua for Toxicity Evaluation of Camptothecin and Hydoxy-Camptothecin
por: Zhang, Lan, et al.
Publicado: (2013) -
Circulating peroxisome proliferator-activated receptor γ is elevated in systemic sclerosis
por: Żółkiewicz, Jakub, et al.
Publicado: (2019) -
Differential induction of Leishmania donovani bi-subunit topoisomerase I–DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I
por: Das, Benu Brata, et al.
Publicado: (2006)